Early detection of skincancer by SkinVision app
Skin cancer has the highest prevalence of all cancers. Melanoma is the most aggressive form. People continue to die of skin cancer due to a delay in diagnosis.
SkinVision aims to save 250,000 lives in the next decade. Due to implementation of SkinVision technology within the care-path starting at the individuals and connecting individuals in time with the right doctors. Doctors use SkinVision as second opinion or first opinion to identify skin cancer.
SkinVision was founded in 2011 in Bucharest, Romania, based on a PhD study to apply the mathematical theory ‘fractal geometry’ for medical imaging. In 2012 the organisation moved to Amsterdam, the Netherlands. The initial founders are still involved in SkinVision and the team is a group of dedicated individuals including a panel of distinguished dermatologists, imaging experts and a scientific board who have clinically validated thousands of skin cancers in 2017 alone. The app is available all over the world except for the United States, and currently implemented in primary care centers to increase the quality of care with new technology.
The core of the SkinVision solution is the camera algorithm. This technology calculates the fractal dimension of skin lesions and surrounding tissue and builds a structural map that reveals abnormal growth patterns.
SkinVision is as accurate as a dermatologist’s eye. The accuracy of the algorithm has been scientifically tested in studies with Ludwig Maximilian University in Germany and the Catharina Hospital in the Netherlands. Testing on the accuracy and sensitivity leads to continous results.
SkinVision is the leading app for early detection of skin cancer. With over 1 million users in 50+ countries worldwide, we are fighting skin cancer on a global scale. The app is capable of detecting Melanoma, Squamous Cell Carcinoma, Basal Cell Carcinoma as well as precancerous Actinic Keratosis. SkinVision has been designed to complement visits to a GP or dermatologist by providing the leading mobile solution for assessing and tracking moles. With an accuracy rate of over 95% for melanoma, the app is more accurate in finding the disease than the average Dermatologist.
Currently the SkinVision technology is implemented in primary care centers and is the reason for applying for the VBHC prize.